UNIVERSITY OF MASSACHUSETTS CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE

该子项目是对CTSA供资的百分比的估计， 用于广泛的研究领域（艾滋病研究，儿科研究，或 临床试验）。 列出的总成本仅为CTSA金额的估算 基础设施走向这一领域的研究，而不是直接提供资金， 向子项目或子项目工作人员提供NCRR补助金。 我们已经建立了马萨诸塞州临床和转化科学中心（UMCCTS），其中包括五个UMass校区的大学。在运作上，该中心位于大学的伍斯特校区，由医学院管理。该中心作为“学术之家”的临床和转化科学家在所有麻省大学校园。CTSA计划将建立在世界级基础科学的基础上的临床和转化研究，2006年诺贝尔生理学或医学奖授予克雷格梅洛和2008年阿尔伯特拉斯克奖授予维克托安布罗斯就是证明。UMCTS的目标是：1）通过招募优秀的T1研究领导者来加速早期转化（T1）研究;建立创新的研究核心设施;并根据麻省大学的发现开发新的疗法，设备和干预措施; 2）整合新英格兰中部和马萨诸塞州独特的临床研究和医疗保健服务网络，以建立和扩大T2（临床有效性研究）和T3通过招募杰出的T2和T3研究领导人，并通过开发创新的T2/T3核心设施，提高（实施和传播研究）能力;并加强患者和社区的外联和参与临床/人口研究; 3）UMCCTS将与麻省大学系统的所有校区和学校合作开发项目，课程和教师支持系统，以促进临床和转化研究的职业生涯。州长德瓦尔帕特里克和马萨诸塞州立法机构最近颁布了一项立法，承诺将10亿美元的州投资用于英联邦的生命科学。凭借9000万美元的种子资金，该大学建立了麻省大学先进治疗学集群（UMATC），其中包括RNA治疗研究所，干细胞生物学和再生医学中心以及基因治疗中心。UMATC加入了马萨诸塞州生物实验室，迈耶斯初级保健研究所和联邦医学，四个创新的组成部分，很少在学术中心发现，以加快工作台到床边社区发现临床和转化研究。相关性（参见说明）：马萨诸塞州大学临床和转化科学中心（UMCCTS）将通过为所有大学临床研究者提供“学术之家”来改变临床和转化研究的行为。UMCCTS将提供强大的试点资助计划，全面的教育和职业发展计划，以及创新的核心设施，以支持和培养临床研究人员。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. We have established the University of Massachusetts Center for Clinical and Translational Science (UMCCTS) which includes the five UMass campuses. Operationally, the Center is located at the University's Worcester campus and managed by the School of Medicine. The Center serves as the "academic home" for clinical and translational scientists across all UMass campuses. The CTSA program will build clinical and translational research upon a foundation of world class basic science as evidenced by the award of the Nobel Prize in Physiology or Medicine to Craig Mello in 2006 and the Albert Lasker Award to Victor Ambros in 2008. The UMCCTS aims are to: 1) Accelerate early phase translational (Tl) studies by recruiting outstanding T1 research leaders; establishing innovative research core facilities; and developing new therapies, devices, and interventions based upon UMass discoveries; 2) Integrate unique networks of clinical research and healthcare delivery in Central New England and Massachusetts at-large to build and expand T2 (clinical effectiveness research) and T3 (implementation and dissemination research) capacity by recruiting outstanding T2 and T3 research leaders, and by developing innovative T2/T3 core facilities; and enhancing patient and community outreach and participation in clinical/population-based research; 3) The UMCCTS will work collaboratively with all campuses and schools ofthe UMass system in developing programs, curricula, and faculty support systems that promote careers in clinical and translational research. Governor Deval Patrick and the Massachusetts Legislature recently enacted legislation committing $1 billion in state investment to be directed to the Life Sciences in the Commonwealth. With $90 million in seed funding, the University has established the UMass Advanced Therapeutics Cluster (UMATC) which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. The UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute, and Commonwealth Medicine, four innovative components that are rarely found in academic centers, to speed bench to bedside to community discoveries in clinical and translational research. RELEVANCE (See instructions): The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will transform the conduct of clinical and translational research by providing an "academic home" for all university clinical investigators. The UMCCTS will provide robust pilot grant programs, comprehensive education and career development programs, and innovative core facilities to support and nurture clinical investigators.